Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Eculizumab in Hemolytic PNH (Open-label, Multicenter)
2004-002795-42Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events, Clinical laboratory data and 2 more. Started Dec 2004; status: completed.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2004-002795-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002795-42.